Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs Author(s): Watson JA, Kissler S, Day NP, Grad YH, White NJ|Journal: medRxiv| January 2021 There is no agreed methodology for pharmacometric assessment of candidate antiviral drugs in COVID-19. The most widely used measure of…
